Here, using a BRAFi‐resistant PDX melanoma model, we demonstrated that SRC inhibition (dasatinib) significantly controlled tumor growth and remarkably re‐sensitize melanoma cells to BRAFi (dabrafenib), doubling the overall survival rate compared to BRAFi alone. This evidence concerns the gene SRC and melanoma.